Bipolar • LB Pharmaceuticals

Now Enrolling
Written By Kirsten Hirst

LB-102-011

About the Study

For adults with a diagnosis of Bipolar I Disorder currently experiencing a Major Depressive Episode (MDE).

The goal of this study is to evaluate the efficacy, safety, and tolerability of LB-102, compared to placebo, in treating depressive symptoms associated with Bipolar I Disorder.

This study is sponsored by LB Pharmaceuticals.

Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18–65 years old

  • have been diagnosed with Bipolar I Disorder and are currently experiencing a depressive episode

  • meet DSM-5 criteria for Bipolar I Disorder

  • are generally in good physical health

  • are willing to discontinue certain psychiatric medications during the study, if required

Apply Today

If you are interested in participating in this clinical trial, please call our friendly staff at 801-871-5516 today. You can also fill out the contact form below.

 
Kirsten Hirst
Next

Anxiety • Reunion